Completed PHASE2 INTERVENTIONAL 3-arm NCT00172094

Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches

A Phase 2 Safety and Efficacy Study of NPS 1776 for the Acute Treatment of Migraine Headaches

Sponsor: Shire

Interventions NPS 1776 (400 mg) NPS 1776 (800 mg) PLACEBO

Updated 7 times since 2017 Last updated: May 30, 2021 Started: Dec 31, 2003 Primary completion: Jun 30, 2004 Completion: Jul 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00172094, this PHASE2 trial focuses on Migraine Headache and remains completed. Sponsored by Shire, it has been updated 7 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Sep 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Sep 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shire

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Chesterfield, United States , Chicago, United States , Greensboro, United States , Houston, United States , Huntsville, United States , Little Rock, United States , Moorestown, United States , Morristown, United States , Oceanside, United States and 12 more locations